RSV vaccines off to a sluggish start in US this season, with volumes behind 2023
This season’s uptake of RSV vaccines in the US has been slower than expected, according to Wall Street analysts tracking prescriptions, and appears to be missing even modest projections for growth...
View ArticleEMA reviews hair loss products following concerns about suicidal thoughts
The European Medicines Agency is looking more closely at medicines used to treat hair loss and a condition caused by an enlarged prostate over concerns about suicidal thoughts. The review encompasses...
View ArticleBARDA doles out $72M to Sanofi, GSK and CSL for bird flu vaccine supply
The Center for Biomedical Advanced Research and Development Authority (BARDA) is giving $72 million to three drugmakers to help fortify the US supply of bird flu vaccine ahead of 2025. The funding was...
View ArticleWuXi companies consider sale of units impacted by Biosecure; J&J, Bayer trim...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleClik here to view.
Pfizer targeted by activist, following post-pandemic stumbles — reports
The activist investor Starboard Value has taken a stake in Pfizer, according to media reports, following the drugmaker’s months of lackluster results as it came out of the pandemic and sought the next...
View ArticleClik here to view.
FDA puts Kezar lupus trial on hold after earlier report of patient deaths
Kezar Life Sciences’ autoimmune drug candidate has been put on hold by the FDA after the company said last week that four patients died in a Phase 2b lupus nephritis trial. The patients were in the...
View ArticleUpstream and CAMP4 target $182M, $67M IPOs
Upstream Bio, a mid-stage respiratory drug developer, and CAMP4 Therapeutics, a Phase 1 regulatory RNA startup, have unveiled the targeted price ranges for their initial public offerings. Upstream is...
View ArticleClik here to view.
Judo Bio launches with $100M for kidney-targeted siRNA therapies
The kidney hasn’t always gotten much love from genetic medicine. The organ is vital to our health, but is often viewed as a liability for drug developers. It can flush out otherwise helpful therapies,...
View ArticleOaktree creates third life sciences SPAC, following success with Hims & Hers...
Global investment manager Oaktree is out with its third life sciences-dedicated special purpose acquisition company after previously using blank checks to take public Hims & Hers and Alvotech in...
View ArticleGalapagos investor gets board seat; OnKure completes merger with Reneo
Plus, news about ViiV’s long-acting PrEP and a newly announced merger: Galapagos investor gets board seat: After building up a stake in the struggling Belgian drugmaker, EcoR1 Capital founder Oleg...
View ArticleClik here to view.
Special report 2024: Meet 20 women breaking new ground in biopharma R&D
Dedicated to the memory of Natalie Grover, who co-created the Women in Biopharma R&D special report while she was a reporter at Endpoints from 2018-2020. Natalie passed away earlier this year, but...
View ArticleAstraZeneca makes another cardio deal, betting $100M on China company’s lipid...
AstraZeneca is strengthening its cardiovascular disease pipeline with a $100 million upfront deal for a lipid-targeting drug from China’s CSPC Pharmaceutical Group. The UK drugmaker will get the rights...
View ArticleScholar Rock claims success in Phase 3 spinal muscular atrophy study, stock...
Scholar Rock announced its experimental add-on treatment for spinal muscular atrophy significantly improved motor function compared to placebo at one year in a pivotal study. The 12-year old biotech...
View ArticlePost-Hoc: What does an activist want with Pfizer?
The news that Pfizer has an activist isn’t a surprise. For the last few months at Endpoints News, we’ve been asking which drugmaker might find an investor in its stock agitating for change. Pfizer...
View ArticleClik here to view.
Liquidia wins with Supreme Court decision to not review Yutrepia-Tyvaso...
Liquidia’s stock $LQDA rose about 10% on Monday following a win in the US Supreme Court for its treprostinil inhalation powder Yutrepia. Liquidia has been fighting United Therapeutics over competing...
View ArticleMany drug price proposals from candidates and Congress won't have much...
Want to lower drug prices? Good luck. In a new report released Friday, the nonpartisan Congressional Budget Office (CBO) detailed how many of the campaign proposals mentioned by presidential nominees...
View ArticleNovo and Viatris settle Ozempic patent suit as generic entry date remains...
Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster diabetes drug Ozempic. The Danish company declined to comment on the terms of its...
View ArticleJ&J’s ‘pretzel’ drug-device therapy fails Phase 3 in certain bladder cancer...
Johnson & Johnson’s drug-device combo has disappointed in a late-stage test in people with an advanced form of bladder cancer, but it says it is still confident in the technology’s overall...
View ArticleClik here to view.
Exclusive: Tiny startup with big vision to extend healthspan by 20 years says...
Last August, stem cell biologist and bit.bio founder Mark Kotter launched a new startup with an ambitious goal: within a year, to identify every gene that plays a role in restoring or repairing aging...
View ArticleMerck partners with small UK biotech to drug fibroblasts for fibrosis, I&I...
As Merck builds out its immunology research lab in London, it’s partnering with a local biotech startup that has remained relatively quiet since its seed round in 2021. The pharma giant said Tuesday...
View Article